How personal loss and hope drove Elaine Maynard’s work in clinical trials and patient-centric technologies

Citius Pharma receives FDA approval for immunotherapy targeting rare blood cancer

Halda Therapeutics raises $126M to take 'hold and kill' precision cancer drugs to the clinic

Gilead gains accelerated FDA approval for rare liver disease treatment

FDA lifts hold on BioNTech and MediLink's ADC trial After safety revisions

Breakthrough delivery system could transform Alzheimer’s treatment

First bispecific CAR-T therapy for MS receives green light from FDA to start phase 1

Breaking News: Lecanemab approved in UK but unavailable on NHS

Highlights

array(40) {
  [0]=>
  string(4) "4558"
  ["article_id"]=>
  string(4) "4558"
  [1]=>
  string(44) "Exosome Based Therapeutic Development Summit"
  ["article_title"]=>
  string(44) "Exosome Based Therapeutic Development Summit"
  [2]=>
  string(150) "The exosome field is evolving rapidly as scientific understanding grows and the industry quickly approaches the stage of entering clinical trials over"
  ["short_description"]=>
  string(150) "The exosome field is evolving rapidly as scientific understanding grows and the industry quickly approaches the stage of entering clinical trials over"
  [3]=>
  string(510) "The exosome field is evolving rapidly as scientific understanding grows and the industry quickly approaches the stage of entering clinical trials over the coming years. If the boom in immunotherapies has told us anything about drug development; it’s being first to market is game changing.&#nlThe inaugural Exosome Based Therapeutic Development Summit 2019 will unite biotech, academia, pharma and technology providers to accelerate the discovery, development and commercialization of safe and effect..."
  ["description"]=>
  string(510) "The exosome field is evolving rapidly as scientific understanding grows and the industry quickly approaches the stage of entering clinical trials over the coming years. If the boom in immunotherapies has told us anything about drug development; it’s being first to market is game changing.&#nlThe inaugural Exosome Based Therapeutic Development Summit 2019 will unite biotech, academia, pharma and technology providers to accelerate the discovery, development and commercialization of safe and effect..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "3"
  ["category"]=>
  string(1) "3"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "58"
  ["rss_id"]=>
  string(2) "58"
  [14]=>
  string(76) "https://www.pharmiweb.com/event/exosome-based-therapeutic-development-summit"
  ["blog_url"]=>
  string(76) "https://www.pharmiweb.com/event/exosome-based-therapeutic-development-summit"
  [15]=>
  string(19) "2019-05-06 18:44:33"
  ["add_date"]=>
  string(19) "2019-05-06 18:44:33"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-09-14 14:32:21"
  ["create_at"]=>
  string(19) "2019-09-14 14:32:21"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Exosome Based Therapeutic Development Summit

The exosome field is evolving rapidly as scientific understanding grows and the industry quickly approaches the stage of

array(40) {
  [0]=>
  string(4) "2477"
  ["article_id"]=>
  string(4) "2477"
  [1]=>
  string(147) "Zynerba Pharmaceuticals Receives Fast Track Designation for Zygel for the Treatment of Behavioral Symptoms Associated with Fragile X Syndrome (FXS)"
  ["article_title"]=>
  string(147) "Zynerba Pharmaceuticals Receives Fast Track Designation for Zygel for the Treatment of Behavioral Symptoms Associated with Fragile X Syndrome (FXS)"
  [2]=>
  string(150) "Devon, PA, May 6, 2019 — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid"
  ["short_description"]=>
  string(150) "Devon, PA, May 6, 2019 — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid"
  [3]=>
  string(249) "Devon, PA, May 6, 2019 — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that the U.S. Food..."
  ["description"]=>
  string(249) "Devon, PA, May 6, 2019 — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that the U.S. Food..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "9"
  ["rss_id"]=>
  string(1) "9"
  [14]=>
  string(238) "https://www.drugs.com/nda/zygel_190506.html?utm_source=ddc&utm_medium=rss&utm_campaign=Zynerba+Pharmaceuticals+Receives+Fast+Track+Designation+for+Zygel+for+the+Treatment+of+Behavioral+Symptoms+Associated+with+Fragile+X+Syndrome+%28FXS%29"
  ["blog_url"]=>
  string(238) "https://www.drugs.com/nda/zygel_190506.html?utm_source=ddc&utm_medium=rss&utm_campaign=Zynerba+Pharmaceuticals+Receives+Fast+Track+Designation+for+Zygel+for+the+Treatment+of+Behavioral+Symptoms+Associated+with+Fragile+X+Syndrome+%28FXS%29"
  [15]=>
  string(19) "2019-05-06 14:05:46"
  ["add_date"]=>
  string(19) "2019-05-06 14:05:46"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-23 14:18:27"
  ["create_at"]=>
  string(19) "2019-05-23 14:18:27"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Zynerba Pharmaceuticals Receives Fast Track Designation for Zygel for the Treatment of Beh

Devon, PA, May 6, 2019 — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-pr

array(40) {
  [0]=>
  string(4) "2104"
  ["article_id"]=>
  string(4) "2104"
  [1]=>
  string(123) "Three weeks left to enter the NutraIngredients-Asia awards...do your products, ingredients and projects have what it takes?"
  ["article_title"]=>
  string(123) "Three weeks left to enter the NutraIngredients-Asia awards...do your products, ingredients and projects have what it takes?"
  [2]=>
  string(150) "There are just three weeks left to submit entries to the second NutraIngredients-Asia Awards, which offer brands, suppliers and researchers the chance"
  ["short_description"]=>
  string(150) "There are just three weeks left to submit entries to the second NutraIngredients-Asia Awards, which offer brands, suppliers and researchers the chance"
  [3]=>
  string(225) "There are just three weeks left to submit entries to the second NutraIngredients-Asia Awards, which offer brands, suppliers and researchers the chance to be crowned the region's brightest and best ahead of Vitafoods Asia."
  ["description"]=>
  string(225) "There are just three weeks left to submit entries to the second NutraIngredients-Asia Awards, which offer brands, suppliers and researchers the chance to be crowned the region's brightest and best ahead of Vitafoods Asia."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "35"
  ["rss_id"]=>
  string(2) "35"
  [14]=>
  string(228) "https://www.nutraingredients-asia.com/Article/2019/05/06/Three-weeks-left-to-enter-the-NutraIngredients-Asia-awards-do-your-products-ingredients-and-projects-have-what-it-takes?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  ["blog_url"]=>
  string(228) "https://www.nutraingredients-asia.com/Article/2019/05/06/Three-weeks-left-to-enter-the-NutraIngredients-Asia-awards-do-your-products-ingredients-and-projects-have-what-it-takes?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  [15]=>
  string(19) "2019-05-06 09:33:00"
  ["add_date"]=>
  string(19) "2019-05-06 09:33:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:41:32"
  ["create_at"]=>
  string(19) "2019-05-09 16:41:32"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Three weeks left to enter the NutraIngredients-Asia awards...do your products, ingredients

There are just three weeks left to submit entries to the second NutraIngredients-Asia Awards, which offer brands, suppli

array(40) {
  [0]=>
  string(4) "2098"
  ["article_id"]=>
  string(4) "2098"
  [1]=>
  string(96) "DuPont to manufacture novel probiotic strain for clinical trial on sepsis in Bangladeshi infants"
  ["article_title"]=>
  string(96) "DuPont to manufacture novel probiotic strain for clinical trial on sepsis in Bangladeshi infants"
  [2]=>
  string(150) "DuPont is manufacturing a new probiotic strain for use in an upcoming large-scale clinical study in Bangladesh, which will test the effects of probiot"
  ["short_description"]=>
  string(150) "DuPont is manufacturing a new probiotic strain for use in an upcoming large-scale clinical study in Bangladesh, which will test the effects of probiot"
  [3]=>
  string(195) "DuPont is manufacturing a new probiotic strain for use in an upcoming large-scale clinical study in Bangladesh, which will test the effects of probiotics on gut microbiome of infants with sepsis."
  ["description"]=>
  string(195) "DuPont is manufacturing a new probiotic strain for use in an upcoming large-scale clinical study in Bangladesh, which will test the effects of probiotics on gut microbiome of infants with sepsis."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "35"
  ["rss_id"]=>
  string(2) "35"
  [14]=>
  string(205) "https://www.nutraingredients-asia.com/Article/2019/05/06/DuPont-to-manufacture-novel-probiotic-strain-for-clinical-trial-on-sepsis-in-Bangladeshi-infants?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  ["blog_url"]=>
  string(205) "https://www.nutraingredients-asia.com/Article/2019/05/06/DuPont-to-manufacture-novel-probiotic-strain-for-clinical-trial-on-sepsis-in-Bangladeshi-infants?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  [15]=>
  string(19) "2019-05-06 09:33:00"
  ["add_date"]=>
  string(19) "2019-05-06 09:33:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:41:32"
  ["create_at"]=>
  string(19) "2019-05-09 16:41:32"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

DuPont to manufacture novel probiotic strain for clinical trial on sepsis in Bangladeshi i

DuPont is manufacturing a new probiotic strain for use in an upcoming large-scale clinical study in Bangladesh, which wi

array(40) {
  [0]=>
  string(4) "1987"
  ["article_id"]=>
  string(4) "1987"
  [1]=>
  string(131) "AveXis Presented Robust Data at AAN Demonstrating Efficacy of Zolgensma in Broad Spectrum of Spinal Muscular Atrophy (SMA) Patients"
  ["article_title"]=>
  string(131) "AveXis Presented Robust Data at AAN Demonstrating Efficacy of Zolgensma in Broad Spectrum of Spinal Muscular Atrophy (SMA) Patients"
  [2]=>
  string(150) "Basel, May 5, 2019 - AveXis, a Novartis company, today announced interim data from ongoing trials of the investigational product Zolgensma (onasemnoge"
  ["short_description"]=>
  string(150) "Basel, May 5, 2019 - AveXis, a Novartis company, today announced interim data from ongoing trials of the investigational product Zolgensma (onasemnoge"
  [3]=>
  string(249) "Basel, May 5, 2019 - AveXis, a Novartis company, today announced interim data from ongoing trials of the investigational product Zolgensma (onasemnogene abeparvovec-xioi; AVXS-101)1 that showed positive results across a broad spectrum of patients..."
  ["description"]=>
  string(249) "Basel, May 5, 2019 - AveXis, a Novartis company, today announced interim data from ongoing trials of the investigational product Zolgensma (onasemnogene abeparvovec-xioi; AVXS-101)1 that showed positive results across a broad spectrum of patients..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(300) "https://www.drugs.com/clinical_trials/avexis-presented-robust-data-aan-demonstrating-efficacy-zolgensma-broad-spectrum-spinal-muscular-18129.html?utm_source=ddc&utm_medium=rss&utm_campaign=AveXis+Presented+Robust+Data+at+AAN+Demonstrating+Efficacy+of+Zolgensma+in+Broad+Spectrum+of+Spinal+Muscular+At"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/clinical_trials/avexis-presented-robust-data-aan-demonstrating-efficacy-zolgensma-broad-spectrum-spinal-muscular-18129.html?utm_source=ddc&utm_medium=rss&utm_campaign=AveXis+Presented+Robust+Data+at+AAN+Demonstrating+Efficacy+of+Zolgensma+in+Broad+Spectrum+of+Spinal+Muscular+At"
  [15]=>
  string(19) "2019-05-06 06:05:58"
  ["add_date"]=>
  string(19) "2019-05-06 06:05:58"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:57"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:57"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

AveXis Presented Robust Data at AAN Demonstrating Efficacy of Zolgensma in Broad Spectrum

Basel, May 5, 2019 - AveXis, a Novartis company, today announced interim data from ongoing trials of the investigational

array(40) {
  [0]=>
  string(4) "2496"
  ["article_id"]=>
  string(4) "2496"
  [1]=>
  string(168) "Cytokinetics Announces Results of FORTITUDE-ALS, a Phase 2 Clinical Trial of Reldesemtiv in Patients With ALS, Presented at American Academy of Neurology Annual Meeting"
  ["article_title"]=>
  string(168) "Cytokinetics Announces Results of FORTITUDE-ALS, a Phase 2 Clinical Trial of Reldesemtiv in Patients With ALS, Presented at American Academy of Neurology Annual Meeting"
  [2]=>
  string(150) "SOUTH SAN FRANCISCO, Calif., May 05, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK, “Cytokinetics”) announced that res"
  ["short_description"]=>
  string(150) "SOUTH SAN FRANCISCO, Calif., May 05, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK, “Cytokinetics”) announced that res"
  [3]=>
  string(251) "SOUTH SAN FRANCISCO, Calif., May 05, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK, “Cytokinetics”) announced that results of FORTITUDE-ALS (Functional Outcomes in a Randomized Trial of Investigational Treatment with..."
  ["description"]=>
  string(251) "SOUTH SAN FRANCISCO, Calif., May 05, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK, “Cytokinetics”) announced that results of FORTITUDE-ALS (Functional Outcomes in a Randomized Trial of Investigational Treatment with..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(300) "https://www.drugs.com/clinical_trials/cytokinetics-announces-results-fortitude-als-phase-2-clinical-trial-reldesemtiv-patients-als-18144.html?utm_source=ddc&utm_medium=rss&utm_campaign=Cytokinetics+Announces+Results+of+FORTITUDE-ALS%2C+a+Phase+2+Clinical+Trial+of+Reldesemtiv+in+Patients+With+ALS%2C+"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/clinical_trials/cytokinetics-announces-results-fortitude-als-phase-2-clinical-trial-reldesemtiv-patients-als-18144.html?utm_source=ddc&utm_medium=rss&utm_campaign=Cytokinetics+Announces+Results+of+FORTITUDE-ALS%2C+a+Phase+2+Clinical+Trial+of+Reldesemtiv+in+Patients+With+ALS%2C+"
  [15]=>
  string(19) "2019-05-05 09:05:49"
  ["add_date"]=>
  string(19) "2019-05-05 09:05:49"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-23 14:18:34"
  ["create_at"]=>
  string(19) "2019-05-23 14:18:34"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Cytokinetics Announces Results of FORTITUDE-ALS, a Phase 2 Clinical Trial of Reldesemtiv i

SOUTH SAN FRANCISCO, Calif., May 05, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK, “Cytokinet

array(40) {
  [0]=>
  string(4) "5316"
  ["article_id"]=>
  string(4) "5316"
  [1]=>
  string(41) "Global Summit on Healthcare and Nutrition"
  ["article_title"]=>
  string(41) "Global Summit on Healthcare and Nutrition"
  [2]=>
  string(150) "Nutrition Congress 2019 has been forecasting and targeting to gather all healthcare and Nutrition experts around the globe to showcase modernizing too"
  ["short_description"]=>
  string(150) "Nutrition Congress 2019 has been forecasting and targeting to gather all healthcare and Nutrition experts around the globe to showcase modernizing too"
  [3]=>
  string(518) "Nutrition Congress 2019 has been forecasting and targeting to gather all healthcare and Nutrition experts around the globe to showcase modernizing tools and research practices in healthcare and Nutrition. Healthcare and Nutrition Congress 2019 will bring you a great platform to learn new methods and modernizations from several experts in this field.&#nlThe session will be systematized around the theme “Modernizing the ethics of Healthcare and Nutrition”&#nlOn behalf of the Nutrition Congress 2019 O..."
  ["description"]=>
  string(518) "Nutrition Congress 2019 has been forecasting and targeting to gather all healthcare and Nutrition experts around the globe to showcase modernizing tools and research practices in healthcare and Nutrition. Healthcare and Nutrition Congress 2019 will bring you a great platform to learn new methods and modernizations from several experts in this field.&#nlThe session will be systematized around the theme “Modernizing the ethics of Healthcare and Nutrition”&#nlOn behalf of the Nutrition Congress 2019 O..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "3"
  ["category"]=>
  string(1) "3"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "58"
  ["rss_id"]=>
  string(2) "58"
  [14]=>
  string(73) "https://www.pharmiweb.com/event/global-summit-on-healthcare-and-nutrition"
  ["blog_url"]=>
  string(73) "https://www.pharmiweb.com/event/global-summit-on-healthcare-and-nutrition"
  [15]=>
  string(19) "2019-05-04 18:19:27"
  ["add_date"]=>
  string(19) "2019-05-04 18:19:27"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-10-31 15:50:28"
  ["create_at"]=>
  string(19) "2019-10-31 15:50:28"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Global Summit on Healthcare and Nutrition

Nutrition Congress 2019 has been forecasting and targeting to gather all healthcare and Nutrition experts around the glo

array(40) {
  [0]=>
  string(4) "2474"
  ["article_id"]=>
  string(4) "2474"
  [1]=>
  string(108) "FDA Approves Genentech's Kadcyla for Adjuvant Treatment of People With HER2-Positive Early Breast Cancer"
  ["article_title"]=>
  string(108) "FDA Approves Genentech's Kadcyla for Adjuvant Treatment of People With HER2-Positive Early Breast Cancer"
  [2]=>
  string(150) "South San Francisco, CA -- May 3, 2019 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and "
  ["short_description"]=>
  string(150) "South San Francisco, CA -- May 3, 2019 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and "
  [3]=>
  string(247) "South San Francisco, CA -- May 3, 2019 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Kadcyla (ado-trastuzumab emtansine) for adjuvant (after..."
  ["description"]=>
  string(247) "South San Francisco, CA -- May 3, 2019 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Kadcyla (ado-trastuzumab emtansine) for adjuvant (after..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "8"
  ["rss_id"]=>
  string(1) "8"
  [14]=>
  string(266) "https://www.drugs.com/newdrugs/fda-approves-genentech-s-kadcyla-adjuvant-her2-positive-early-breast-cancer-4963.html?utm_source=ddc&utm_medium=rss&utm_campaign=FDA+Approves+Genentech%27s+Kadcyla+for+Adjuvant+Treatment+of+People+With+HER2-Positive+Early+Breast+Cancer"
  ["blog_url"]=>
  string(266) "https://www.drugs.com/newdrugs/fda-approves-genentech-s-kadcyla-adjuvant-her2-positive-early-breast-cancer-4963.html?utm_source=ddc&utm_medium=rss&utm_campaign=FDA+Approves+Genentech%27s+Kadcyla+for+Adjuvant+Treatment+of+People+With+HER2-Positive+Early+Breast+Cancer"
  [15]=>
  string(19) "2019-05-04 06:05:33"
  ["add_date"]=>
  string(19) "2019-05-04 06:05:33"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-23 14:18:27"
  ["create_at"]=>
  string(19) "2019-05-23 14:18:27"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

FDA Approves Genentech's Kadcyla for Adjuvant Treatment of People With HER2-Positive E

South San Francisco, CA -- May 3, 2019 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today ann

array(40) {
  [0]=>
  string(4) "2115"
  ["article_id"]=>
  string(4) "2115"
  [1]=>
  string(74) "Bellicum Pharma’s Grossman Joins Arcus Bio as Chief Medical Officer"
  ["article_title"]=>
  string(74) "Bellicum Pharma’s Grossman Joins Arcus Bio as Chief Medical Officer"
  [2]=>
  string(150) "William Grossman has joined Arcus Biosciences (NYSE: RCUS) as chief medical officer, the same position he held at his former company, Bellicum Pharmac"
  ["short_description"]=>
  string(150) "William Grossman has joined Arcus Biosciences (NYSE: RCUS) as chief medical officer, the same position he held at his former company, Bellicum Pharmac"
  [3]=>
  string(399) "William Grossman has joined Arcus Biosciences (NYSE: RCUS) as chief medical officer, the same position he held at his former company, Bellicum Pharmaceuticals (NASDAQ: BLCM). Grossman’s experience also includes positions at Genentech, AbbVie (NYSE: ABBV), and Biothera. Hayward, CA-based Arcus, which raised $120 million in its IPO last year, has several cancer drugs in early-stage […]"
  ["description"]=>
  string(399) "William Grossman has joined Arcus Biosciences (NYSE: RCUS) as chief medical officer, the same position he held at his former company, Bellicum Pharmaceuticals (NASDAQ: BLCM). Grossman’s experience also includes positions at Genentech, AbbVie (NYSE: ABBV), and Biothera. Hayward, CA-based Arcus, which raised $120 million in its IPO last year, has several cancer drugs in early-stage […]"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "36"
  ["rss_id"]=>
  string(2) "36"
  [14]=>
  string(112) "https://xconomy.com/san-francisco/2019/05/03/bellicum-pharmas-grossman-joins-arcus-bio-as-chief-medical-officer/"
  ["blog_url"]=>
  string(112) "https://xconomy.com/san-francisco/2019/05/03/bellicum-pharmas-grossman-joins-arcus-bio-as-chief-medical-officer/"
  [15]=>
  string(19) "2019-05-04 05:59:33"
  ["add_date"]=>
  string(19) "2019-05-04 05:59:33"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:41:33"
  ["create_at"]=>
  string(19) "2019-05-09 16:41:33"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Bellicum Pharma’s Grossman Joins Arcus Bio as Chief Medical Officer

William Grossman has joined Arcus Biosciences (NYSE: RCUS) as chief medical officer, the same position he held at his fo

array(40) {
  [0]=>
  string(4) "2116"
  ["article_id"]=>
  string(4) "2116"
  [1]=>
  string(57) "Athira Pharma Appoints Hans Moebius Chief Medical Officer"
  ["article_title"]=>
  string(57) "Athira Pharma Appoints Hans Moebius Chief Medical Officer"
  [2]=>
  string(155) "Hans Moebius has joined Athira Pharma as chief medical officer. Moebius’s experience includes positions at Ciba-Geigy, Novartis (NYSE: NVS), Merz Ph"
  ["short_description"]=>
  string(155) "Hans Moebius has joined Athira Pharma as chief medical officer. Moebius’s experience includes positions at Ciba-Geigy, Novartis (NYSE: NVS), Merz Ph"
  [3]=>
  string(407) "Hans Moebius has joined Athira Pharma as chief medical officer. Moebius’s experience includes positions at Ciba-Geigy, Novartis (NYSE: NVS), Merz Pharma, TauRx, and Allergan (NYSE: AGN). Seattle-based Athira, which recently changed its name from M3 Biotechnology, is currently testing lead drug candidate NDX-1017 in a Phase 1 study in patients with Alzheimer’s disease, dementia, or […]"
  ["description"]=>
  string(407) "Hans Moebius has joined Athira Pharma as chief medical officer. Moebius’s experience includes positions at Ciba-Geigy, Novartis (NYSE: NVS), Merz Pharma, TauRx, and Allergan (NYSE: AGN). Seattle-based Athira, which recently changed its name from M3 Biotechnology, is currently testing lead drug candidate NDX-1017 in a Phase 1 study in patients with Alzheimer’s disease, dementia, or […]"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "36"
  ["rss_id"]=>
  string(2) "36"
  [14]=>
  string(97) "https://xconomy.com/seattle/2019/05/03/athira-pharma-appoints-hans-moebius-chief-medical-officer/"
  ["blog_url"]=>
  string(97) "https://xconomy.com/seattle/2019/05/03/athira-pharma-appoints-hans-moebius-chief-medical-officer/"
  [15]=>
  string(19) "2019-05-04 05:48:29"
  ["add_date"]=>
  string(19) "2019-05-04 05:48:29"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:41:33"
  ["create_at"]=>
  string(19) "2019-05-09 16:41:33"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Athira Pharma Appoints Hans Moebius Chief Medical Officer

Hans Moebius has joined Athira Pharma as chief medical officer. Moebius’s experience includes positions at Ciba-G

array(40) {
  [0]=>
  string(4) "2026"
  ["article_id"]=>
  string(4) "2026"
  [1]=>
  string(43) "FDA Offers Advice to Sponsors of ADHD Drugs"
  ["article_title"]=>
  string(43) "FDA Offers Advice to Sponsors of ADHD Drugs"
  [2]=>
  string(153) "&#nl        The FDA released a draft guidance for sponsors of stimulant drugs for treating attention deficit hyperactivity disorder (ADHD) with recommend"
  ["short_description"]=>
  string(153) "&#nl        The FDA released a draft guidance for sponsors of stimulant drugs for treating attention deficit hyperactivity disorder (ADHD) with recommend"
  [3]=>
  string(216) "&#nl        The FDA released a draft guidance for sponsors of stimulant drugs for treating attention deficit hyperactivity disorder (ADHD) with recommendations for clinical trials and new drug applications.&#nl      "
  ["description"]=>
  string(216) "&#nl        The FDA released a draft guidance for sponsors of stimulant drugs for treating attention deficit hyperactivity disorder (ADHD) with recommendations for clinical trials and new drug applications.&#nl      "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "16"
  ["rss_id"]=>
  string(2) "16"
  [14]=>
  string(83) "https://www.fdanews.com/articles/191176-fda-offers-advice-to-sponsors-of-adhd-drugs"
  ["blog_url"]=>
  string(83) "https://www.fdanews.com/articles/191176-fda-offers-advice-to-sponsors-of-adhd-drugs"
  [15]=>
  string(19) "2019-05-04 05:09:59"
  ["add_date"]=>
  string(19) "2019-05-04 05:09:59"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:57"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:57"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

FDA Offers Advice to Sponsors of ADHD Drugs

&#nl The FDA released a draft guidance for sponsors of stimulant drugs for treating attention deficit hyperactivi

array(40) {
  [0]=>
  string(4) "2147"
  ["article_id"]=>
  string(4) "2147"
  [1]=>
  string(49) "What Makes Two Materials “Identical”?"
  ["article_title"]=>
  string(49) "What Makes Two Materials “Identical”?"
  [2]=>
  string(153) "&#nlOn April 26, FDA released a final guidance on Characterization of Ultrahigh Molecular Weight Polyethylene (UHMWPE) Used in Orthopedic Dev"
  ["short_description"]=>
  string(153) "&#nlOn April 26, FDA released a final guidance on Characterization of Ultrahigh Molecular Weight Polyethylene (UHMWPE) Used in Orthopedic Dev"
  [3]=>
  string(6402) "&#nl
On April 26, FDA released a final guidance on Characterization of Ultrahigh Molecular Weight Polyethylene (UHMWPE) Used in Orthopedic Devices1. The draft of this guidance was issued on February 12, 2016. The guidance addresses four different types of UHMWPE: conventional, highly crosslinked, highly crosslinked containing antioxidants, and non-conventional. The parameters of characterization include material description, sterility, biocompatibility, mechanical properties, and chemical properties. For the base material, FDA “recommends” the inclusion of information on starting resin, resin consolidation method, and the terminal sterilization method. Material properties of interest, depending on the type of UHMWPE, include tensile properties, impact resistance, density, crosslinking parameters, percent crystallinity, melting temperature, fatigue resistance, antioxidants used, effect of antioxidant on wear, creep resistance, and surface durability. These many parameters, and the allowable ranges in relevant standards, demonstrate that material characterization is a complex issue.
&#nl
Yet in the section on biocompatibility, FDA states that “If the subject device uses the identical UHMWPE materials and manufacturing processes as a legally marketed device with a history of safe use, you may reference previous testing experience or literature, if appropriate.” It is not explained exactly what such referencing buys you. The italics "in identical" are FDA’s, but there is no definition given of identical and the word does not appear elsewhere in the standard.
&#nl
What then makes two pieces of UHMPE identical? This would seem to go beyond the name, any relevant standards, and the supplier. More generally, identical would seem to require that every characteristic of the material (such as those enumerated in the guidance) have been shown to match between the previously used material and the candidate material. This would presumably require proof obtained from testing. And such proof would seem to also require biocompatibility testing--i.e., you have to do all the tests to show that it is identical before you can assert that it is identical. This is reminiscent of an observation under Design Controls pertaining to risk assessment. Under validation (21CFR820.30g) there is a requirement that risk assessment be included “where appropriate.” This of course invites the question, When is it appropriate? The preamble to the regulation provides a partial answer “Risk analysis must be conducted for the majority of devices subject to design controls and is considered to be an essential requirement for medical devices.” A further answer heard from FDA is that in order to determine whether a risk analysis is appropriate, you have to do the risk analysis.
&#nl
Another component of identical is identified in the use of Master Files, which are supplied to FDA by material manufacturers. However, it isn’t just about the raw material, because FDA recommends that the possible effects of processing, cleaning, and sterilization of the finished device also be assessed. Despite the requirement for “identical,” FDA seems to waffle a bit by allowing for a prior device with “similar location/duration of contact and intended use that uses the same materials and manufacturing processes.” Since biocompatibility is now understood to be application specific, a “similar” use of the same material lowers the bar. FDA also says that, in addition, conformity to a recognized material consensus standard can be declared when applicable. While such conformity may be relevant, it generally would not rise to the level of “identical” since most standards are inexact. For example, ASTM 648, Standard Specification for Ultra-High-Molecular-Weight Polyethylene Powder and Fabricated Form for Surgical Implants, allows for a range of densities and three types with different strengths and other mechanical properties. FDA further notes that antioxidants and wear debris are a consideration for UHMWPE biocompatibility. Wear is at least in part a function of the design of the device and its specific application, which further makes “similar” a loose term.
&#nl
Implant material science is receiving increased FDA attention as reflected by this guidance, FDA’s general statement on materials2, and the recent draft guidance on Nitinol3. It would appear that FDA will be increasing its scrutiny of regulatory submissions in this regard, and that the “regulatory burden” will increase accordingly.
&#nl
References
&#nl
  1. https://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance...
    2. &#nl
  2. https://www.fda.gov/news-events/press-announcements/statement-fda-commis...
    3. &#nl
  3. https://www.fda.gov/media/123272/download
    4. &#nl
"
  ["description"]=>
  string(6402) "&#nl
On April 26, FDA released a final guidance on Characterization of Ultrahigh Molecular Weight Polyethylene (UHMWPE) Used in Orthopedic Devices1. The draft of this guidance was issued on February 12, 2016. The guidance addresses four different types of UHMWPE: conventional, highly crosslinked, highly crosslinked containing antioxidants, and non-conventional. The parameters of characterization include material description, sterility, biocompatibility, mechanical properties, and chemical properties. For the base material, FDA “recommends” the inclusion of information on starting resin, resin consolidation method, and the terminal sterilization method. Material properties of interest, depending on the type of UHMWPE, include tensile properties, impact resistance, density, crosslinking parameters, percent crystallinity, melting temperature, fatigue resistance, antioxidants used, effect of antioxidant on wear, creep resistance, and surface durability. These many parameters, and the allowable ranges in relevant standards, demonstrate that material characterization is a complex issue.
&#nl
Yet in the section on biocompatibility, FDA states that “If the subject device uses the identical UHMWPE materials and manufacturing processes as a legally marketed device with a history of safe use, you may reference previous testing experience or literature, if appropriate.” It is not explained exactly what such referencing buys you. The italics "in identical" are FDA’s, but there is no definition given of identical and the word does not appear elsewhere in the standard.
&#nl
What then makes two pieces of UHMPE identical? This would seem to go beyond the name, any relevant standards, and the supplier. More generally, identical would seem to require that every characteristic of the material (such as those enumerated in the guidance) have been shown to match between the previously used material and the candidate material. This would presumably require proof obtained from testing. And such proof would seem to also require biocompatibility testing--i.e., you have to do all the tests to show that it is identical before you can assert that it is identical. This is reminiscent of an observation under Design Controls pertaining to risk assessment. Under validation (21CFR820.30g) there is a requirement that risk assessment be included “where appropriate.” This of course invites the question, When is it appropriate? The preamble to the regulation provides a partial answer “Risk analysis must be conducted for the majority of devices subject to design controls and is considered to be an essential requirement for medical devices.” A further answer heard from FDA is that in order to determine whether a risk analysis is appropriate, you have to do the risk analysis.
&#nl
Another component of identical is identified in the use of Master Files, which are supplied to FDA by material manufacturers. However, it isn’t just about the raw material, because FDA recommends that the possible effects of processing, cleaning, and sterilization of the finished device also be assessed. Despite the requirement for “identical,” FDA seems to waffle a bit by allowing for a prior device with “similar location/duration of contact and intended use that uses the same materials and manufacturing processes.” Since biocompatibility is now understood to be application specific, a “similar” use of the same material lowers the bar. FDA also says that, in addition, conformity to a recognized material consensus standard can be declared when applicable. While such conformity may be relevant, it generally would not rise to the level of “identical” since most standards are inexact. For example, ASTM 648, Standard Specification for Ultra-High-Molecular-Weight Polyethylene Powder and Fabricated Form for Surgical Implants, allows for a range of densities and three types with different strengths and other mechanical properties. FDA further notes that antioxidants and wear debris are a consideration for UHMWPE biocompatibility. Wear is at least in part a function of the design of the device and its specific application, which further makes “similar” a loose term.
&#nl
Implant material science is receiving increased FDA attention as reflected by this guidance, FDA’s general statement on materials2, and the recent draft guidance on Nitinol3. It would appear that FDA will be increasing its scrutiny of regulatory submissions in this regard, and that the “regulatory burden” will increase accordingly.
&#nl
References
&#nl
  1. https://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance...
    2. &#nl
  2. https://www.fda.gov/news-events/press-announcements/statement-fda-commis...
    3. &#nl
  3. https://www.fda.gov/media/123272/download
    4. &#nl
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "40"
  ["rss_id"]=>
  string(2) "40"
  [14]=>
  string(61) "https://www.mddionline.com/what-makes-two-materials-identical"
  ["blog_url"]=>
  string(61) "https://www.mddionline.com/what-makes-two-materials-identical"
  [15]=>
  string(19) "2019-05-04 04:54:08"
  ["add_date"]=>
  string(19) "2019-05-04 04:54:08"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:41:39"
  ["create_at"]=>
  string(19) "2019-05-09 16:41:39"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

What Makes Two Materials “Identical”?